[18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)

This multicenter center, open-label, baseline-controlled diagnostic imaging study designed to assess the use of Fluorthanatrace-Positron Emission tomography (FTT-PET) as a PARP inhibitor (PARPi) therapy predictive imaging biomarker and the use of EnhanceAR-Seq (ctDNA) in predicting response to therapy and to identify genomic alterations associated with resistance. Furthermore, to correlate changes in ctDNA and imaging (FTT-PET and standard of care imaging) to understand the dynamics of tumor response.

NCT Number	NCT07723651
Lead Sponsor	Washington University School of Medicine Collaborators: National Cancer Institute (NCI)
Conditions	Metastatic Prostate Cancer, Prostate Cancer
Enrollment	75 participants
Start Date	2026-09-01
Primary Completion	2032-03-31 (estimated)
Study Completion	2032-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-23